Skip to main content
Year archive

ADALTA LIMITED — 2020 filings

All 72 regulatory filings released by ADALTA LIMITED (1AD) in 2020, sourced directly from the official regulator.

72 Filings
2020 Period
2020 filings (72)
Filing Released Lang
Phase I HV extension to explore encouraging results 2 pages 304.1KB
Regulatory Filings
2020-12-13 English
Change of Director's Interest Notice 2 pages 261.5KB
Director's Dealing
2020-11-29 English
Constitution 50 pages 431.8KB
Governance Information
2020-11-25 English
AGM Presentation 28 pages 15.6MB
AGM Information
2020-11-24 English
Results of Meeting 2 pages 24.5KB
Declaration of Voting Results & Voting Rights Announcements
2020-11-24 English
AGM joining and voting instructions 7 pages 1.1MB
AGM Information
2020-11-22 English
Notification of Expired Options 2 pages 299.0KB
Share Issue/Capital Change
2020-11-08 English
AusBiotech presentation including Phase I status update 15 pages 9.9MB
Investor Presentation
2020-10-26 English
Annual General Meeting - Letter to Shareholders 2 pages 812.6KB
AGM Information
2020-10-21 English
Notice of Annual General Meeting/Proxy Form 20 pages 698.4KB
AGM Information
2020-10-21 English
R&D Tax Incentive Refund received 2 pages 292.6KB
Regulatory Filings
2020-10-18 English
Quarterly Appendix 4C and Activities Report 9 pages 444.3KB
Interim / Quarterly Report
2020-10-11 English
Response to ASX Price Query 5 pages 1.1MB
Regulatory Filings
2020-10-08 English
Investor Presentation - BIO investor forum 30 pages 11.7MB
Investor Presentation
2020-10-08 English
Change in substantial holding 3 pages 121.8KB
Major Shareholding Notification
2020-10-06 English
Broader role for CXCR4 in fibrosis 2 pages 314.3KB
Regulatory Filings
2020-09-29 English
Adjustment to Option Exercise Prices 2 pages 299.3KB
Capital/Financing Update
2020-09-24 English
GE Healthcare collaboration progresses 2 pages 296.4KB
Regulatory Filings
2020-09-20 English
Change in substantial holding 2 pages 84.7KB
Major Shareholding Notification
2020-09-14 English
Appendix 2A and Cleansing Notice 16 pages 1.2MB
Regulatory Filings
2020-09-10 English
Change in Director Interest Notice x 4 11 pages 340.7KB
Director's Dealing
2020-09-09 English
Appendix 2A and Cleansing Notice 16 pages 1.2MB
Capital/Financing Update
2020-09-08 English
Appendix 2A and Cleansing Notice 16 pages 1.2MB
Capital/Financing Update
2020-09-07 English
Rights Issue results 3 pages 330.5KB
Capital/Financing Update
2020-09-06 English
Proposed issue of Securities - 1AD 5 pages 27.7KB
Capital/Financing Update
2020-09-06 English
Proposed issue of Securities - 1AD 5 pages 27.7KB
Capital/Financing Update
2020-09-06 English
Preliminary Final Report 2 pages 136.3KB
Earnings Release
2020-08-26 English
Annual Report to shareholders 64 pages 5.8MB
Regulatory Filings
2020-08-26 English
Appendix 4G and Corporate Governance Statement 21 pages 565.6KB
Governance Information
2020-08-26 English
Change in substantial holding 3 pages 144.1KB
Major Shareholding Notification
2020-08-24 English
Becoming a substantial holder 2 pages 24.1KB
Major Shareholding Notification
2020-08-23 English
Non-renounceable Rights Issue Offer 38 pages 1.3MB
Capital/Financing Update
2020-08-18 English
Despatch of Rights Offer Documents 4 pages 1.2MB
Capital/Financing Update
2020-08-18 English
Appendix 2A and Cleansing Notice 16 pages 1.2MB
Regulatory Filings
2020-08-17 English
Change in substantial holding 2 pages 101.4KB
Major Shareholding Notification
2020-08-17 English
Placement and Rights Offer 3 pages 349.1KB
Capital/Financing Update
2020-08-10 English
Proposed issue of Securities - 1AD 5 pages 28.1KB
Capital/Financing Update
2020-08-10 English
Proposed issue of Securities - 1AD 7 pages 33.2KB
Capital/Financing Update
2020-08-10 English
Letter to Optionholders 2 pages 952.7KB
Capital/Financing Update
2020-08-10 English
Cleansing Notice - Rights Offer 2 pages 976.3KB
Capital/Financing Update
2020-08-10 English
Trading Halt 2 pages 1.0MB
Capital/Financing Update
2020-08-06 English
Investor presentation including future milestones 25 pages 15.3MB
Investor Presentation
2020-07-29 English
AdAlta to present at IRD Invest virtual conference 2 pages 293.9KB
Investor Presentation
2020-07-23 English
First participants treated in AD-214 Phase I trial 2 pages 298.4KB
Regulatory Filings
2020-07-22 English
David Fuller appointed as non-executive director 2 pages 294.7KB
Board/Management Information
2020-07-21 English
Initial Director's Interest Notice 2 pages 163.0KB
Director's Dealing
2020-07-21 English
Quarterly Appendix 4C and Activities Report 8 pages 422.2KB
Interim / Quarterly Report
2020-07-20 English
Supportive US FDA pre-IND meeting results for AD-214 3 pages 309.6KB
Regulatory Filings
2020-07-19 English
AdAlta to present at TechKnow Invest Webinar 20 pages 10.3MB
Investor Presentation
2020-06-14 English
AdAlta receives approval to commence AD-214 Phase I trial 3 pages 773.7KB
Regulatory Filings
2020-06-09 English
BIO Presentation 19 pages 9.7MB
Investor Presentation
2020-06-04 English
Investor Presentation 20 pages 3.5MB
Investor Presentation
2020-04-29 English
Quarterly Appendix 4C and Activities Report 10 pages 406.0KB
Interim / Quarterly Report
2020-04-28 English
Business update and COVID-19 response 4 pages 356.3KB
Capital/Financing Update
2020-03-30 English
Final Director's Interest Notice x 2 4 pages 294.9KB
Director's Dealing
2020-03-29 English
Board changes and R&D Tax Incentive advance received 3 pages 309.1KB
Board/Management Information
2020-03-26 English
Appendix 3G 13 pages 275.2KB
Share Issue/Capital Change
2020-03-22 English
Issuance and cancellation of options 2 pages 840.3KB
Share Issue/Capital Change
2020-03-22 English
Change of Director's Interest Notice 2 pages 260.5KB
Director's Dealing
2020-03-09 English
CXCR4 in fibrosis publication 2 pages 316.0KB
Regulatory Filings
2020-03-09 English
Investor Briefing - Strategic Plan 70 pages 11.4MB
Investor Presentation
2020-03-02 English
AD-214 effective in gold standard pre-clinical animal model 3 pages 374.1KB
Regulatory Filings
2020-03-01 English
AD-214 PK and PD support Phase I weekly dosing objective 3 pages 265.3KB
Capital/Financing Update
2020-03-01 English
Half Yearly Report and Accounts 23 pages 981.0KB
Interim / Quarterly Report
2020-02-25 English
Investor strategy briefing scheduled 2 pages 311.6KB
Regulatory Filings
2020-02-16 English
AdAlta updated corporate presentation 30 pages 4.8MB
Investor Presentation
2020-02-09 English
Appendix 4C - quarterly 9 pages 522.0KB
Interim / Quarterly Report
2020-01-30 English
AdAlta Granted US Patent for AD-214 2 pages 817.0KB
Regulatory Filings
2020-01-29 English
Appendix 3B 13 pages 525.0KB
Capital/Financing Update
2020-01-20 English
AD-214 Phase I strategy and timing update 3 pages 870.8KB
Regulatory Filings
2020-01-13 English
Director Resignation 2 pages 198.9KB
Board/Management Information
2020-01-02 English
Final Director's Interest Notice 2 pages 225.9KB
Director's Dealing
2020-01-02 English